Meeting
2013 ASCO Annual Meeting
Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT.
Authors
Alessandra Gennari
E.O. Ospedali Galliera, Genoa, Italy
Alessandra Gennari , Dino Amadori , Etienne Brain , Javier Cortes , Nadia Harbeck , Matteo Puntoni , Rachel Wuerstlein , Oriana Nanni , Eva Muñoz-Couselo , Giovanni Paganelli , Maribel Lopera Sierra , Federica Matteucci , Arnoldo Piccardo Sr., Paolo Bruzzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
2013-000287-29
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS649)
DOI
10.1200/jco.2013.31.15_suppl.tps649
Abstract #
TPS649
Poster Bd #
14H
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Chemotherapy shows better efficacy than endocrine therapy in patients with metastatic breast cancer with heterogeneous estrogen receptor expression.
First Author: Yizhao Xie
Poster
2020 ASCO Virtual Scientific Program
Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC).
First Author: Joline Si Jing Lim
Poster
2019 ASCO Annual Meeting
Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.
First Author: Muriel Laine
Poster
2018 ASCO Annual Meeting
PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.
First Author: Francois Clement Bidard